Egret Therapeutics, a Portfolio Company of Turret Capital Management, Announces FDA Approval of its IND Application for EGT 101
NEW YORK, February 4, 2023 /PRNewswire/ — Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the United States Food and Drug Administration (FDA) has cleared its application for Investigational New Drug (IND) for EGT 101 which is being investigated for the treatment of delayed cerebral ischemia (DCI) secondary to aneurysmal subarachnoid hemorrhage. The phase I/II trial is expected to start enrolling patients in 2023.
“We are delighted to have received IND clearance for our aneurysmal subarachnoid hemorrhage program,” said Daniel Chai, MD, co-founder and CEO of Egret Therapeutics. “The clearance of this IND is a testament to the hard work and deep commitment of the Egret team to bring drugs to market that will help patients,” said Henry ParkChief Financial Officer of Egret Therapeutics.
Among patients with subarachnoid hemorrhage (SAH) who survive initial bleeding from a ruptured aneurysm, delayed cerebral ischemia (DCI) is the most important preventable cause of mortality and poor neurological prognosis. “The prevention of IBD has been a focus of SAH research for decades, but there are few clinical options today. We are excited to move forward with our clinical development of EGT. 101 in hopes of bringing therapy to patients for whom there is a high unmet need,” said chris jacksonMD, co-founder and medical director of Egret Therapeutics.
About Egret Therapeutics
Egret Therapeutics is a clinical-stage biotherapeutics company. The Company is focused on developing products to address unmet clinical needs in neurological diseases.
For more information, visit us at www.egrettherapeutics.com
SOURCE Turret Capital Management
